A citation-based method for searching scientific literature

Moa Lugner, Naveed Sattar, Mervete Miftaraj, Jan Ekelund, Stefan Franzén, Ann-Marie Svensson, Björn Eliasson. Cardiovasc Diabetol 2021
Times Cited: 6







List of co-cited articles
21 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
66

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
Rury R Holman, M Angelyn Bethel, Robert J Mentz, Vivian P Thompson, Yuliya Lokhnygina, John B Buse, Juliana C Chan, Jasmine Choi, Stephanie M Gustavson, Nayyar Iqbal,[...]. N Engl J Med 2017
829
50

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
634
50

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
50

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
700
50

Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Elisabetta Patorno, Allison B Goldfine, Sebastian Schneeweiss, Brendan M Everett, Robert J Glynn, Jun Liu, Seoyoung C Kim. BMJ 2018
88
50

Cardiovascular Outcomes with GLP-1 Receptor Agonists Versus SGLT-2 Inhibitors in Patients with Type 2 Diabetes.
Caroline H Nørgaard, Liis Starkopf, Thomas A Gerds, Peter Vestergaard, Anders N Bonde, Emil Fosbøl, Lars Køber, Nathan D Wong, Christian Torp-Pedersen, Christina J-Y Lee. Eur Heart J Cardiovasc Pharmacother 2021
3
100

Comparative Effectiveness and Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults.
Elisabetta Patorno, Ajinkya Pawar, Lily G Bessette, Dae H Kim, Chintan Dave, Robert J Glynn, Medha N Munshi, Sebastian Schneeweiss, Deborah J Wexler, Seoyoung C Kim. Diabetes Care 2021
10
50

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetologia 2020
171
50

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life.
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lorenzo Gubian, Angelo Avogaro, Gian Paolo Fadini. BMJ Open Diabetes Res Care 2020
16
50

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
33

10-year follow-up of intensive glucose control in type 2 diabetes.
Rury R Holman, Sanjoy K Paul, M Angelyn Bethel, David R Matthews, H Andrew W Neil. N Engl J Med 2008
33


GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas. Hellenic J Cardiol 2019
19
33

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.
Suetonia C Palmer, Britta Tendal, Reem A Mustafa, Per Olav Vandvik, Sheyu Li, Qiukui Hao, David Tunnicliffe, Marinella Ruospo, Patrizia Natale, Valeria Saglimbene,[...]. BMJ 2021
60
33

A real-world comparison of cardiovascular, medical and costs outcomes in new users of SGLT2 inhibitors versus GLP-1 agonists.
Insiya B Poonawalla, Andy T Bowe, Michael C Tindal, Yunus A Meah, Phil Schwab. Diabetes Res Clin Pract 2021
3
66


Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
271
33


Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
399
33

Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.
Hertzel C Gerstein, Naveed Sattar, Julio Rosenstock, Chinthanie Ramasundarahettige, Richard Pratley, Renato D Lopes, Carolyn S P Lam, Nardev S Khurmi, Laura Heenan, Stefano Del Prato,[...]. N Engl J Med 2021
28
33

GLP-1 influences food and drug reward.
Matthew R Hayes, Heath D Schmidt. Curr Opin Behav Sci 2016
47
16

Glucagon-Like Peptide-1 (GLP-1) and 5-Hydroxytryptamine 2c (5-HT2c) Receptor Agonists in the Ventral Tegmental Area (VTA) Inhibit Ghrelin-Stimulated Appetitive Reward.
Erin Howell, Hannah M Baumgartner, Lia J Zallar, Joaquín A Selva, Liv Engel, Paul J Currie. Int J Mol Sci 2019
14
16


Biology of incretins: GLP-1 and GIP.
Laurie L Baggio, Daniel J Drucker. Gastroenterology 2007
16

Longer-term liraglutide administration at the highest dose approved for obesity increases reward-related orbitofrontal cortex activation in response to food cues: Implications for plateauing weight loss in response to anti-obesity therapies.
Olivia M Farr, Jagriti Upadhyay, Chelsea Rutagengwa, Bridget DiPrisco, Zachary Ranta, Amal Adra, Neha Bapatla, Vivian P Douglas, Konstantinos A A Douglas, Eric Nolen-Doerr,[...]. Diabetes Obes Metab 2019
9
16

The incretin effect in obese adolescents with and without type 2 diabetes: impaired or intact?
Benedikt A Aulinger, Torsten P Vahl, Ron L Prigeon, David A D'Alessio, Deborah A Elder. Am J Physiol Endocrinol Metab 2016
9
16

Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia.
Mahesh M Umapathysivam, Michael Y Lee, Karen L Jones, Christopher E Annink, Caroline E Cousins, Laurence G Trahair, Chris K Rayner, Marianne J Chapman, Michael A Nauck, Michael Horowitz,[...]. Diabetes 2014
79
16

Intermedin in paraventricular nucleus attenuates sympathetic activity and blood pressure via nitric oxide in hypertensive rats.
Ye-Bo Zhou, Hai-Jian Sun, Dan Chen, Tong-Yan Liu, Ying Han, Jue-Jin Wang, Chao-Shu Tang, Yu-Ming Kang, Guo-Qing Zhu. Hypertension 2014
25
16

Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
16


Sympathetic activation in obese normotensive subjects.
G Grassi, G Seravalle, B M Cattaneo, G B Bolla, A Lanfranchi, M Colombo, C Giannattasio, A Brunani, F Cavagnini, G Mancia. Hypertension 1995
453
16


SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.
Michael J Jurczak, Hui-Young Lee, Andreas L Birkenfeld, Francois R Jornayvaz, David W Frederick, Rebecca L Pongratz, Xiaoxian Zhao, Gilbert W Moeckel, Varman T Samuel, Jean M Whaley,[...]. Diabetes 2011
147
16

Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes.
Hsien-Yen Chang, Sonal Singh, Omar Mansour, Sheriza Baksh, G Caleb Alexander. JAMA Intern Med 2018
63
16

Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Rosemary H Elliott, Vance B Matthews, Caroline Rudnicka, Markus P Schlaich. Nephrology (Carlton) 2016
13
16

Vagal mediation of GLP-1's effects on food intake and glycemia.
Jean-Philippe Krieger, Wolfgang Langhans, Shin J Lee. Physiol Behav 2015
29
16

SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging.
Jennifer R Matthews, Lakshini Y Herat, Aaron L Magno, Shelley Gorman, Markus P Schlaich, Vance B Matthews. Biomedicines 2020
3
33

Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy.
Mumin Alper Erdogan, Dimas Yusuf, Joanna Christy, Volkan Solmaz, Arife Erdogan, Emin Taskiran, Oytun Erbas. BMC Neurol 2018
14
16

Possible role of brain salt-inducible kinase 1 in responses to central sodium in Dahl rats.
Bing S Huang, Roselyn A White, Frans H H Leenen. Am J Physiol Regul Integr Comp Physiol 2012
7
16

Sodium-coupled glucose cotransporters contribute to hypothalamic glucose sensing.
Dervla O'Malley, Frank Reimann, Anna K Simpson, Fiona M Gribble. Diabetes 2006
90
16






Direct and indirect effects of liraglutide on hypothalamic POMC and NPY/AgRP neurons - Implications for energy balance and glucose control.
Zhenyan He, Yong Gao, Linh Lieu, Sadia Afrin, Jianhong Cao, Natalie J Michael, Yanbin Dong, Jia Sun, Hongbo Guo, Kevin W Williams. Mol Metab 2019
20
16

High salt intake increases blood pressure via BDNF-mediated downregulation of KCC2 and impaired baroreflex inhibition of vasopressin neurons.
Katrina Y Choe, Su Y Han, Perrine Gaub, Brent Shell, Daniel L Voisin, Blayne A Knapp, Philip A Barker, Colin H Brown, J Thomas Cunningham, Charles W Bourque. Neuron 2015
77
16

Type 2 diabetes.
Sudesna Chatterjee, Kamlesh Khunti, Melanie J Davies. Lancet 2017
673
16

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A DeFronzo. Diabetes Care 2016
189
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.